In the GeViro! powerpoint presentation, on the PharmaTech website, Monoclonal Antibodies are mentioned quite frequently. Since you claim to know so much about the process, and it's clear that you are here to cast doubt on the DECN technology, and even convince shareholders that this is not a good investment, maybe you can enlighten us.

Please explain to us, specifically, what is bad science, or misleading on the GenViro! presentation. The presentation has been available for quite a while now, so I would think that someone like you can dissect it and discredit it.

Will you do us that favor?